After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
REGN belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Regeneron Pharmaceuticals, Inc is $84.19B. A total of 1.05 million shares were traded on the day, compared to an average of 1.01M shares.
In the most recent transaction, Bassler Bonnie L sold 1,500 shares of REGN for 800.00 per share on Jan 07 ’26. After the transaction, the Director now owns 1,703 company shares. In a previous transaction on Jan 07 ’26, Bassler Bonnie L bought 1,500 shares at 800.00 per share.
Among the insiders who sold shares, Bassler Bonnie L disposed of 760 shares on Nov 20 ’25 at a per-share price of $750.00. This resulted in the Director holding 1,548 shares of REGN after the transaction. In another insider transaction, Bassler Bonnie L bought 760 shares at $750.00 per share on Nov 20 ’25.
Dividend
Paying dividends generates immediate cash flow for investors and indicates a positive outlook for the company. Regeneron Pharmaceuticals, Inc pays an annual dividend of $3.52, resulting in a dividend yield of 0.44%, and it has a price to earnings (P/E) ratio of 19.18.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, REGN has a high of $814.10 and a low of $476.49.
As of this writing, REGN has an earnings estimate of $10.58 per share for the current quarter. EPS was calculated based on a consensus of 20.0 estimates, with a high estimate of $12.85 per share and a lower estimate of $8.89. The company reported an EPS of $12.07 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. REGN’s latest balance sheet shows that the firm has $5.69B in Cash & Short Term Investments as of fiscal 2021. There were $2.70B in debt and $3.93B in liabilities at the time. Its Book Value Per Share was $294.00, while its Total Shareholder’s Equity was $18.77B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for REGN is Buy with a score of 4.41.
